Telomir Pharmaceuticals (TELO)

• Market cap: $154M
• 1 day: 14.10%
• 5 days: 1.57%
• 1 month: 23.33%
• 3 months: -33.93%
• 6 months: 3.19%
• Year to date: 3.60%
• 1 year: 3.60%
• 5 years: 3.60%
• 10 years: 3.60%
• Sector: Healthcare
• Industry: Pharmaceutical Preparations

About: Telomir Pharmaceuticals Inc is a pioneering preclinical-stage pharmaceutical company leading the advancement of age-reversal science. The Company is focused on developing Telomir-1, a novel small molecule designed to lengthen and protect telomeres-the protective DNA end caps of chromosomes that are crucial to cellular aging. As humans and animals age, telomeres naturally shorten, with metal reactivity accelerating this process, increasing the risk of degenerative and age-related diseases. By addressing the underlying causes of aging at the cellular level, Telomir aims to tackle the root of these conditions rather than simply treating their symptoms. Telomir is conducting ongoing preclinical research into Progeria, diabetes, cancer, Alzheimer's disease, osteoarthritis, and others.

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

900% more first-time investments, than exits

New positions opened: 10 | Existing positions closed: 1

645% more capital invested

Capital invested by funds: $1.76M [Q2] → $13.1M (+$11.4M) [Q3]

180% more repeat investments, than reductions

Existing positions increased: 14 | Existing positions reduced: 5

36% more funds holding

Funds holding: 25 [Q2] → 34 (+9) [Q3]

5.67% more ownership

Funds ownership: 1.24% [Q2] → 6.91% (+5.67%) [Q3]